Oestrogen plus progestin significantly improves bone mineral density and reduces risk of fracture - 24/08/11
Abstract |
Question |
Does oestrogen plus progestin affect bone mineral density and the risk of fracture in healthy post-menopausal women?
Study design |
Double blind randomised controlled trial.
Main results |
Hormone therapy significantly reduced the risk of fracture compared with placebo. Hormone therapy reduced the risk of hip fracture by 33% (see Table 1). At 3 years, bone mineral density (BMD) improved in the hormone group compared with placebo (increase in hip BMD 3.7% vs. 0.14%, mean difference 3.6%, p<0.001; mean difference in lumbar spine BMD 4.5%).
|
Authors’ conclusions |
Oestrogen plus progestin significantly increased bone mineral density and reduced risk of fracture in healthy post-menopausal women.
Le texte complet de cet article est disponible en PDF.Keywords : Oestrogen replacement therapy, Osteoporosis, Fractures, Postmenopausal women, Randomised controlled trial
Plan
Abstracted from: Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003; 290: 1729–1738. |
Vol 8 - N° 2
P. 102-104 - avril 2004 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?